BioNTech’s Oncology Ambitions Gain Momentum with Promising Trial Data
08.12.2025 - 20:21:05 | boerse-global.de
For investors in BioNTech, the company’s long-stated pivot beyond its COVID-19 vaccine foundation has awaited concrete validation. This week, the Mainz-based biotech firm delivered compelling evidence on two critical fronts, bolstering confidence in its strategic direction. The dual announcements of encouraging late-stage cancer trial results and significant progress in acquiring rival CureVac have provided a much-needed lift to market sentiment.
Parallel to its internal research milestones, BioNTech’s external growth strategy is moving forward. Reports indicate that CureVac shareholders have approved the takeover offer by a substantial majority. This clearance effectively removes the final major hurdle to integrating CureVac’s research pipeline and intellectual property into BioNTech’s portfolio. Read more...
So schätzen die Börsenprofis BioNTech’s Aktien ein!
Für. Immer. Kostenlos.
